Patel Purvee D, Chalouhi Nohra, Atallah Elias, Tjoumakaris Stavropoula, Hasan David, Zarzour Hekmat, Rosenwasser Robert, Jabbour Pascal
Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania.
Department of Neurological Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey; and.
Neurosurg Focus. 2017 Jun;42(6):E4. doi: 10.3171/2017.3.FOCUS1742.
The Pipeline embolization device (PED) is the most widely used flow diverter in endovascular neurosurgery. In 2011, the device received FDA approval for the treatment of large and giant aneurysms in the internal carotid artery extending from the petrous to the superior hypophyseal segments. However, as popularity of the device grew and neurosurgeons gained more experience, its use has extended to several other indications. Some of these off-label uses include previously treated aneurysms, acutely ruptured aneurysms, small aneurysms, distal circulation aneurysms, posterior circulation aneurysms, fusiform aneurysms, dissecting aneurysms, pseudoaneurysms, and even carotid-cavernous fistulas. The authors present a literature review of the safety and efficacy of the PED in these off-label uses.
管道栓塞装置(PED)是血管内神经外科手术中应用最广泛的血流导向装置。2011年,该装置获得美国食品药品监督管理局(FDA)批准,用于治疗从岩骨段至垂体上缘段的颈内动脉大型和巨大动脉瘤。然而,随着该装置的普及以及神经外科医生积累了更多经验,其应用范围已扩展至其他多种适应症。其中一些非标签用途包括既往治疗过的动脉瘤、急性破裂的动脉瘤、小型动脉瘤、远端循环动脉瘤、后循环动脉瘤、梭形动脉瘤、夹层动脉瘤、假性动脉瘤,甚至颈动脉海绵窦瘘。作者对PED在这些非标签用途中的安全性和有效性进行了文献综述。